ancer is one of the leading causes of death worldwide. The oncology drug market reached USD 107 billion in 2015 growing at a compounded 7% per year resulting in most major pharmaceutical companies researching into this therapy area. Meabco A/S is developing two products addressing many of the difficult challenges of cancer treatment and is attempting to close the gaps and offer the following advantages:
- An effective treatment option for cancer patients, especially for those in the late-stage.
- Less toxicity, thus reduced side-effects.
- Improved quality of life during treatment.
- Patient friendly de-centralized treatment.